This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – October 16, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report), Gilead Sciences Inc. (GILD - Analyst Report), GlaxoSmithKline plc (GSK - Analyst Report), Actelion Ltd. (ALIOF) and United Therapeutics Corporation (UTHR - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Arena Pharma Initiates PAH Study
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) recently initiated a phase I multiple dose study with APD811, which is being developed for the treatment of pulmonary arterial hypertension (PAH).
Arena Pharma is expecting to enroll 30 healthy adult volunteers for this randomized, double-blind and placebo-controlled dose titration trial. The trial will study the safety, tolerability and pharmacokinetics of the candidate.
We note that the PAH market already has players like Gilead Sciences Inc. (GILD - Analyst Report), GlaxoSmithKline plc (GSK - Analyst Report), Actelion Ltd. (ALIOF) and United Therapeutics Corporation (UTHR - Analyst Report).
Meanwhile, Arena Pharma achieved a major milestone in June this year when the US Food and Drug Administration (FDA) approved Belviq as an adjunct to a healthy diet (low on calories) and increased physical activity for chronic weight management in obese (Body Mass Index, or BMI, ≥30) or overweight (BMI ≥27) adults suffering from at least one weight-related co-morbid condition. The move marks the first FDA approval for a weight-loss drug in 13 years.
The safety and efficacy of Belviq when co-administered with other weight loss products and the effect on cardiovascular morbidity and mortality are yet to be established. Hence, the FDA recommended Belviq to be classified by the US Drug Enforcement Administration (DEA) as a scheduled drug.
Belviq is currently under review in the EU and the company has filed a marketing application in Switzerland. Arena Pharma and Eisai have a partnership agreement for Belviq.
We currently have a Neutral recommendation on Arena Pharma. The stock carries a Zacks #3 Rank (short-term Hold rating).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339